Articles with public access mandates - Robert KyleLearn more
Not available anywhere: 20
Diagnosis of smoldering multiple myeloma
SV Rajkumar, D Larson, RA Kyle
New England journal of medicine 365 (5), 474-475, 2011
Mandates: US National Institutes of Health
A modern primer on light chain amyloidosis in 592 patients with mass spectrometry–verified typing
E Muchtar, MA Gertz, RA Kyle, MQ Lacy, D Dingli, N Leung, FK Buadi, ...
Mayo Clinic Proceedings 94 (3), 472-483, 2019
Mandates: US National Institutes of Health
Heavy-chain disease
DL Wahner-Roedler, RA Kyle
Neoplastic Diseases of the Blood, 701-728, 2013
Mandates: US National Institutes of Health
Presentation and outcomes of localized immunoglobulin light chain amyloidosis: the Mayo Clinic experience
TV Kourelis, RA Kyle, D Dingli, FK Buadi, SK Kumar, MA Gertz, MQ Lacy, ...
Mayo Clinic proceedings 92 (6), 908-917, 2017
Mandates: US National Institutes of Health
Clinical course and prognosis of non‐secretory multiple myeloma
SS Chawla, SK Kumar, A Dispenzieri, AJ Greenberg, DR Larson, RA Kyle, ...
European journal of haematology 95 (1), 57-64, 2015
Mandates: US National Institutes of Health
Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria
E Muchtar, A Dispenzieri, N Leung, MQ Lacy, FK Buadi, D Dingli, ...
Leukemia 32 (10), 2240-2249, 2018
Mandates: US National Institutes of Health
Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance
A Lakshman, S Paul, SV Rajkumar, RP Ketterling, PT Greipp, ...
Leukemia 32 (8), 1811-1815, 2018
Mandates: US National Institutes of Health
Antibodies to myelin‐associated glycoprotein (anti‐Mag) in IgM amyloidosis may influence expression of neuropathy in rare patients
M Garces‐Sanchez, PJ Dyck, RA Kyle, S Zeldenrust, Y Wu, SS Ladha, ...
Muscle & nerve 37 (4), 490-495, 2008
Mandates: US National Institutes of Health
Clinical features and treatment outcomes of patients with necrobiotic xanthogranuloma associated with monoclonal gammopathies
LS Higgins, RS Go, D Dingli, SK Kumar, SV Rajkumar, A Dispenzieri, ...
Clinical Lymphoma Myeloma and Leukemia 16 (8), 447-452, 2016
Mandates: US National Institutes of Health
Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis
E Muchtar, MA Gertz, TV Kourelis, S Sidana, RS Go, MQ Lacy, FK Buadi, ...
Leukemia 34 (4), 1135-1143, 2020
Mandates: US National Institutes of Health
A pharmacovigilance signaling system based on FDA regulatory action and post-marketing adverse event reports
KB Hoffman, M Dimbil, NP Tatonetti, RF Kyle
Drug safety 39, 561-575, 2016
Mandates: US National Institutes of Health, American Heart Association
Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse
S Sidana, N Tandon, A Dispenzieri, MA Gertz, FK Buadi, MQ Lacy, ...
Leukemia 33 (3), 730-738, 2019
Mandates: US National Institutes of Health
Implications of detecting serum monoclonal protein by MASS‐fix following stem cell transplantation in multiple myeloma
JP Abeykoon, DL Murray, I Murray, D Jevremovic, GE Otteson, ...
British journal of haematology 193 (2), 380-385, 2021
Mandates: US National Institutes of Health
Waldenström's macroglobulinemia
RA Kyle, S Hayman
Advances in Malignant Hematology, 342-354, 2011
Mandates: US National Institutes of Health
Monoclonal gammopathy of undetermined significance: indications for prediagnostic testing, subsequent diagnoses, and follow-up practice at Mayo clinic
A Ravindran, KA Lackore, AE Glasgow, MT Drake, MA Hobbs, T Kourelis, ...
Mayo Clinic Proceedings 95 (5), 944-954, 2020
Mandates: US National Institutes of Health
Criteria for diagnosis and response
RA Kyle, SV Rajkumar
Multiple Myeloma: Diagnosis and Treatment, 1-15, 2013
Mandates: US National Institutes of Health
Treatment and outcome of newly diagnosed multiple myeloma patients> 75 years old: a retrospective analysis
AS Al Saleh, A Visram, H Parmar, E Muchtar, FK Buadi, A Dispenzieri, ...
Leukemia & Lymphoma 62 (12), 3011-3018, 2021
Mandates: US National Institutes of Health
Success of the autologous stem cell boost after autologous graft failure in multiple myeloma and AL amyloidosis
J Cook, WI Gonsalves, MA Gertz, A Visram, R Warsame, MQ Lacy, ...
Bone Marrow Transplantation 57 (6), 1007-1009, 2022
Mandates: US National Institutes of Health
Daratumumab, Carfilzomib, Pomalidomide and Elotuzumab for the Treatment of POEMS Syndrome-The Mayo Clinic Experience
I Vaxman, S Kumar, F Buadi, M Lacy, D Dingli, S Hayman, T Kourelis, ...
Mandates: US National Institutes of Health
MM-315: Impact of Stratification of Levels of Serum Lactate Dehydrogenase (LDH) at Diagnosis on Overall Survival (OS) in Newly Diagnosed Multiple Myeloma (NDMM)
LA Evans, SK Kumar, A Dispenzieri, FK Buadi, D Dingli, MQ Lacy, ...
Clinical Lymphoma Myeloma and Leukemia 21, S435, 2021
Mandates: US National Institutes of Health
Publication and funding information is determined automatically by a computer program